Nathan Fitzsimmons Email

Acting CEO . Dyve Biosciences

Current Roles

Employees:
16
Revenue:
$2.5M
About
About Dyve Biosciences Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout. Dyve’s transdermal delivery science platform overturns the traditional limitations of administering therapies. It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs. For more information, please visit www.dyvebio.com. Corporate Contact Jim McGee Dyve Biosciences, Inc. 805-857-6449 jim.mcgee@dyvebio.com Investor Contact Corey Davis LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com
Dyve Biosciences Address
2545 W Hillcrest Dr
Thousand Oaks, CA
Dyve Biosciences Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.